MF59 adjuvant: the best insurance against influenza strain diversity

@article{Ohagan2011MF59AT,
  title={MF59 adjuvant: the best insurance against influenza strain diversity},
  author={D. O'hagan and R. Rappuoli and E. De Gregorio and T. Tsai and G. del Giudice},
  journal={Expert Review of Vaccines},
  year={2011},
  volume={10},
  pages={447 - 462}
}
MF59 is a well-established, safe and potent vaccine adjuvant that has been licensed for more than 13 years for use in an influenza vaccine focused on elderly subjects (Fluad®, Novartis, Cambridge, MA, USA). Recently, MF59 was shown to be safe in a seasonal influenza vaccine for young children and was able to increase vaccine efficacy from 43 to 89%. A key and consistent feature of MF59 is the ability of the emulsion to induce fast priming of influenza antigen-specific CD4+ T-cell responses, to… Expand
114 Citations
MF59 adjuvanted seasonal and pandemic influenza vaccines.
  • T. Tsai
  • Medicine
  • Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • 2011
  • 29
Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine
  • PDF
Immunology and efficacy of MF59-adjuvanted vaccines
  • 17
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant
  • 30
The mechanism of action of MF59 - an innately attractive adjuvant formulation.
  • 258
  • Highly Influenced
The seasonal influenza vaccine Agriflu®
  • 3
Adjuvanted vaccines against influenza in the elderly
  • 1
Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
  • 29
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 119 REFERENCES
Seasonal Influenza Vaccine Provides Priming for A/H1N1 Immunization
  • 48
...
1
2
3
4
5
...